index

ROBERT J. BALCH Senior Vice President

In addition to being experienced venture capital investors, the backgrounds of Cycad Group’s investment team include substantial experience in entrepreneurial management, finance, law, marketing, and business development.

PAUL F. GLENN Chairman & Director

K. LEONARD JUDSON President & Managing Director

Chairman & Director

PAUL F. GLENN

K. LEONARD JUDSON President & Managing Director

K. LEONARD JUDSON

BIOGRAPHIES

ROBERT J. BALCH Senior Vice President

K. LEONARD JUDSONis the President and Managing Director of Cycad Group. Prior to co-founding Cycad Group in 2000, he practiced law for 14 years and was a partner in two law firms. Throughout his legal career a substantial portion of his practice was devoted to representing both companies and investors in corporate finance, mergers and acquisitions. Leonard’s entrepreneurial and management skills were further enhanced when he co-founded the law firm of May, Potenza, Judson and Baran, P.C., and served as its CEO until his departure to the Cycad Group. Leveraging upon his experience interning for the SEC while in law school and his subsequent securities law practice, Leonard was as a member of the NASD Board of Arbitrators from 1989 to 2002 and chaired a number of securities industry related arbitrations. Among his activities at Cycad Group, Leonard serves as a Director or observer to the board of directors of several of Cycad Group’s portfolio companies including, ImaginAb, Nanosteel Corporation, Sofie Biosciences, and Lixivia. Leonard has previously been a director or board observer on the boards of Genocea Biosciences (Nasdaq NM: GNCA) and Clean Diesel Technologies, Inc. (Nasdaq NM: CDTI), GRT, Inc., ZT3 Technologies and Agile RF. Leonard also serves as a Director and the CEO of the Glenn Foundation For Medical Research, Inc., a non-profit foundation supporting research to understand the biology of aging with the objective of developing interventions to extend the healthy years of human life. Leonard holds a J.D. with Honors, from George Washington University, Washington, D.C., and a B.S. degree, Cum Laude, from Northern Arizona University.

PAUL F. GLENN Chairman & Director

ROBERT J. BALCH

PAUL F. GLENN

ROBERT J. BALCHSince joining Cycad Group in 2004 Bob has been instrumental in founding and financing a number of companies across all investment areas and stages. Bob has served as a director or observer to the board of directors of a number of portfolio companies, including ClarVista Medical, Iosil Energy, Lixivia, Sofie, SteriFx, SpectraFluidics and Agile RF. Prior to joining Cycad Group, Bob was a founding partner of Taraval Associates Seed Capital Fund; a venture fund specializing early stage life sciences companies. As part of his activities with TASCF, Bob spent significant time working in Australia and New Zealand with entrepreneurs, government agencies and the venture capital communities (funding three companies and serving on the board of directors of one). Bob brings extensive operations and management experience to his venture capital activities. Early in his career Bob worked in sales and marketing in the pharmaceutical and medical device industries. He was also among the earliest employees in two healthcare startups: EndoTherapeutics (minimally invasive surgery) and Tokos Medical (perinatal monitoring). Bob then spent 11 years with Mark Products, Inc., a telecommunications company. He was the General Manager of Mark Products, with responsibility for all aspects the business when he left to form Taraval Associates Seed Capital Fund in 1997. Bob holds a B.Sc. in Biological Sciences from California State University, Sacramento, and an M.B.A. from the University of Phoenix.

PAUL F. GLENNis the Chairman and a Director of Cycad Group and was the driving force behind its creation. After spending several years on Wall Street, Paul left the investment banking firms and pursued a career of trading commodities and securities for his own account. His success in these areas led him to the world of private equity and venture capital where he became an early stage investor in a number of companies that have gone public or were acquired by public companies. He is a graduate of Princeton where he received a BA with high honors and also holds a J.D. from Harvard Law School. In 1965 Paul also founded the Glenn Foundation for Medical Research, a 501(c)(3) non-profit foundation devoted to supporting research to understand the biology that governs human aging and its related physiological decline, with the objective of developing interventions that will extend the healthy years of human life. The Foundation has been a leader in funding research in the science of the biology of aging for more than 40 years. Paul continues to serve as the Chairman and visionary for the Glenn Foundation.

PAUL F. GLENN

K. LEONARD JUDSON

ROBERT J. BALCH

PAUL F. GLENNis the Chairman and a Director of Cycad Group and was the driving force behind its creation. After spending several years on Wall Street, Paul left the investment banking firms and pursued a career of trading commodities and securities for his own account. His success in these areas led him to the world of private equity and venture capital where he became an early stage investor in a number of companies that have gone public or were acquired by public companies. He is a graduate of Princeton where he received a BA with high honors and also holds a J.D. from Harvard Law School. In 1965 Paul also founded the Glenn Foundation for Medical Research, a 501(c)(3) non-profit foundation devoted to supporting basic research in the molecular biology of aging and age related diseases. The Foundation has been a leader in funding basic research in the science of aging for more than 40 years. Paul continues to serve as the Chairman and visionary for the Glenn Foundation.

Cycad Group is a venture capital firm focusing on investments in companies with enabling solutions, disruptive technologies and innovative products. We seek opportunities to work with exceptional entrepreneurs creating technology driven businesses. Cycad Group is opportunistic and doesn’t limit its investment activities to any single industry sector. However, we actively pursue investment opportunities in the areas of life sciences (e.g., therapeutics, medical devices, diagnostics and analytical tools), energy technologies, and advanced materials and chemical processes. We have experience investing in companies at all stages of development, from the first round of outside financing to PIPE transactions. At each stage of investment, we strive to understand the fundamental questions about technology, opportunities, management teams and risks. Cycad Group, LLC1270 Coast Village Circle, Suite 100 Santa Barbara, CA 93108805.684.6515 fax: 805.684.6511 ©2018 Cycad Group, LLC

Cycad Group is opportunistic and doesn’t limit its investment activities to any single industry sector. However, we actively pursue investment opportunities in the areas of life sciences (e.g. therapeutics, medical devices, diagnostics and analytical tools), energy technologies and advanced materials and chemical processes. We have experience investing in companies at all stages of development, from the first round of outside financing to PIPE transactions. At each stage of investment, we strive to understand the fundamental questions about technology, opportunities, management teams and risks.

Cycad Group is opportunistic and doesn’t limit its investment activities to any single industry sector. However, we actively pursue investment opportunities in the areas of life sciences (e.g., therapeutics, medical devices, diagnostics and analytical tools), energy technologies, and advanced materials and chemical processes. We have experience investing in companies at all stages of development, from the first round of outside financing to PIPE transactions. At each stage of investment, we strive to understand the fundamental questions about technology, opportunities, management teams and risks.

Our preferred investment strategy is to make an early stage initial investment and then participate in follow-on financings that support the portfolio company’s growth as it reaches its milestones. We also prefer to make investments with other experienced investors who will continue to support the company as it grows. Accordingly, we seek to co-invest with other venture capital funds and corporate venture teams. Given the right opportunity we will lead a round of financing, but we are also comfortable participating as part of an investor syndicate. Cycad Group searches for investments in which the risks associated with technology and market development have been adequately addressed. We look for: outstanding entrepreneurial management teams capable of executing their vision; enabling solutions, disruptive technologies and/or innovative products; sustainable competitive advantages and/or high barriers to entry such as unique and defensible intellectual property; large, well defined growing markets with revenue potential exceeding $100 million; scalable well defined business models that demonstrate great growth potential; and an identified exit strategy/liquidity event. Once we make an investment, Cycad Group views it role as that of a partner; providing enthusiastic support and constructive criticism. As an active advisor to the company we provide entrepreneurs with access to resources that go beyond the investment of capital. We do not want to become involved in the day-to-day management of our portfolio companies. Rather, we look to help enable strong management teams as advisors, assisting management in the development and execution of business and financial strategies. We often seek board observation rights, or where appropriate (given the size of investment, the stage of the company, and other investor representation), the right to designate a representative to the board of directors of a portfolio company. Cycad Group, LLC1270 Coast Village Circle, Suite 100 Santa Barbara, CA 93108805.684.6515 fax: 805.684.6511 ©2018 Cycad Group, LLC

We also prefer to make investments with other experienced investors who will continue to support the company as it grows. Accordingly, we seek to co-invest with other venture capital funds and corporate venture teams. Given the right opportunity we will lead a round of financing, but we are also comfortable participating as part of an investor syndicate.

Cycad Group searches for investments in which the risks associated with technology and market development have been adequately addressed. We look for: outstanding entrepreneurial management teams capable of executing their vision; enabling solutions, disruptive technologies and/or innovative products; sustainable competitive advantages and/or high barriers to entry such as unique and defensible intellectual property; large, well defined growing markets with revenue potential exceeding $100 million; scalable well defined business models that demonstrate great growth potential; and an identified exit strategy/liquidity event.

Once we make an investment, Cycad Group views it role as that of a partner; providing enthusiastic support and constructive criticism. As an active advisor to the company we provide entrepreneurs with access to resources that go beyond the investment of capital. We do not want to become involved in the day-to-day management of our portfolio companies. Rather, we look to help enable strong management teams as advisors, assisting management in the development and execution of business and financial strategies. We often seek board observation rights, or where appropriate (given the size of investment, the stage of the company, and other investor representation), the right to designate a representative to the board of directors of a portfolio company.

Our preferred investment strategy is to make an early stage initial investment and then participate in follow-on financings that support the portfolio company’s growth as it reaches its milestones.

805.684.6515

Visterra, Inc.Visterra uses its proprietary computational technology to generates unique information that guides the discovery and development of novel antibodies for the treatment and prevention of major diseases. The company’s lead product candidates are a broad spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza, and an antibody to treat all four strains of dengue virus.

Agile RF, Inc.

Tilford Pinson Exploration, LLC / Pittsburg GatheringTilford Pinson Exploration, LLC (TPX) is an oil and gas exploration and development company focused in the Arkoma Basin of southeastern Oklahoma. TPX employs state-of-the-art technology to maximize production in the short term while creating long term value via future drilling opportunities. Pittsburg Gathering LLC designs, builds, and operates natural gas gathering systems.

Clean Diesel Technologies /Catalytic Solutions The combined entity of Clean Diesel Technologies (CDTI) and Catalytic Solutions, Inc. (CSI) is a vertically integrated global manufacturer and distributor of emissions control systems and products. It is focused on the heavy duty diesel and light duty vehicle markets. CSI invented Mixed Phase Catalyst technology, a fundamentally unique and patented materials technology for the development of catalysts for emissions control and chemical processes. CDTI and CSI merged in December 2010 (NasdaqCM:CDTI).

Centaur Pharmaceuticals Corporation/Renovis Centaur Pharmaceuticals developed a novel class of small molecule pharmaceutical compounds for the treatment of neurodegenerative and inflammatory diseases such as acute stroke, dementia, rheumatoid arthritis, myocardial ischemia and Parkinson’s disease. Renovis is a biopharmaceutical company with a primary focus on the discovery, development and commercialization of drugs to treat neurological diseases and disorders. Renovis acquired Centaur Pharmaceuticals, Inc. in December 2002 (NasdaqGM:RNVS).

Ovascience, Inc.

Centaur Pharmaceuticals / Renovis

GRT, Inc.GRT, Inc. has developed proprietary process chemistry that converts methane to gasoline or other hydrocarbon fuels and chemicals. The GRT process is highly flexible and can be applied to make a wide variety of high volume chemicals and liquid fuels including olefins, aromatics, and high octane gasoline blend stocks. Unlike current technologies (Fischer-Tropsch chemistry and thermal cracking), GRT’s technology does not require high temperatures or pressures to create the gas to liquids reactions, thus providing significant savings in capital costs and operating expenses. GRT has licensed certain of its key technologies to Marathon Oil Corporation (NYSE:MRO).

Universal Space Network

Intarcia Therapeutics, Inc.

Advanced Bionics

The Nanosteel Company

Advanced Bionics Advanced Bionics® is dedicated to the development of neurostimulation products: implantable devices that generate sophisticated electrical pulses directed to nerves and muscles for the treatment of disabling conditions. Advanced Bionics technologies include treatments for deafness and chronic pain. The company is also developing other sophisticated neurostimulation devices to address additional challenges in many fields including blindness, tremor and spasticity, urinary incontinence, and functional restoration of paralyzed limbs. Advanced Bionics has been acquired by Boston Scientific Corporation.

The Nanosteel CompanyNanoSteel combines the compelling attributes of iron-based alloys with new chemistries and mechanisms to deliver material properties and performance characteristics outside the boundaries of existing steels. NanoSteel has created progressive generations of iron-based alloys from metallic coatings to foils to powder metals and sheet steel. Current focus areas are strong and formable sheet steels (a combination of high strength and high ductility in cold formable steel) for automotive lightweighting applications and hard metal powders for 3D printing.

Fziomed Inc.FzioMed is engaged in the development and commercialization of advanced, absorbable biosurgery products. FzioMed’s product platform is an innovative polymer technology called Oxiplex®. The properties of Oxiplex make it an ideal and versatile biosurgery material. A key focus for use of Oxiplex® is the prevention of post-surgical adhesions. Adhesions are abnormal fibrous bands of scar tissue that form attachments to normally independent organs and tissues. Adhesions create complications which may require further surgical intervention.

Intarcia Therapeutics, Inc. Intarcia is developing innovative therapies utilizing its Medici Drug Delivery System™ that can transform the prevention and management of serious chronic diseases by optimizing the efficacy, continuous administration and tolerability of drug therapies. The Medici Drug Delivery System™ is a proprietary subcutaneous delivery system comprised of: a technology that stabilizes proteins, peptides, antibody fragments, and other highly potent small molecules at or above human body temperatures for three years or more; a matchstick-sized osmotic pump that is placed just under the skin to deliver a continuous and consistent flow of medication; and placement technology. Intarcia is currently using the Medici Drug Delivery System™ to target Type 2 Diabetes.

Lixivia

Calimmune

Tilford Pinson Exploration

Sterifx, Inc.

Lixivia, Inc.Lixivia applies proprietary processes and bio-derived/inspired chemicals to dramatically improve the recovery of precipitated calcium carbonates, calcium salts and rare earth metals from industrial mineral waste products.

Ziopharm Oncology, Inc.

Solaria Corp.Solaria Corp. manufactures low-concentration photovoltaic modules designed for ground-mounted tracking systems. Solaria’s proprietary manufacturing processes require only a fraction of the capital per watt of manufacturing capacity needed by standard industry processes. Based on its patented technology, Solaria’s modules provide reliable performance while matching form, fit and performance of conventional PV modules.

Clean Diesel Technologies

Imaginab, Inc.

Genocea BiosciencesGenocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. The Company has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea uses ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018.

Urban Electric Power, Inc.Urban Electric Power (UEP) is commercializing proprietary zinc anode rechargeable battery technology for applications ranging from car batteries, to power protection to grid-scale storage. UEP technology uses non-toxic, 100% recyclable materials without lead, heavy metals, or flammable electrolytes. UEP offers substantial cost benefits compared to existing battery chemistries because of the extended cycle life, high capacity at high charge/discharge rates, and low cost of starting materials.

Sterifx, Inc.SteriFx, Inc. is a specialty chemical company producing non-toxic antimicrobial solutions for the food safety, industrial, consumer, healthcare, and military/homeland defense markets. The patented technology is a low pH (<1) aqueous solution that is highly effective in controlling pathogens (viruses, bacteria and fungi) with no toxicity when properly used. In addition, SteriFx products are friendlier to the environment (low phosphates and no chlorine) and do not have the harmful effects on processing equipment or work surfaces typically associated with chemicals of similar efficacy. The Company’s products have received regulatory approvals from the USDA/FSIS, EPA and FDA for a variety of applications. SteriFx was acquired in a private transaction.

Alsius Corporation

GRT, Inc.

Solaria Corp.

Visterra, Inc.

Ovascience, Inc.OvaScience is focused on the discovery, development and commercialization of new treatments for female infertility. Utilizing patented technology, OvaScience is translating innovative research in egg precursor germline stem cells to make in vitro fertilization (IVF) safer and more effective (Nasdaq:OVAS).

Clarvista Medical Inc. ClarVista has developed the Harmoni modular intra-ocular lens system. The two piece Harmoni IOL system enables vision optimization through better initial positioning of the lens, and the safe and easy exchange of the lens optic when required. Initial studies also indicate that the risk of development of secondary cataracts is significantly reduced by the Harmoni system. ClarVista has been acquired by Alcon, a division of Novartis (NYSE:NVS)

Clarvista Medical Inc.

Unity Biotechnology, Inc.Unity focuses on the development of therapeutics that extend the human healthspan through intervention in the biological mechanisms associated with aging, thus enabling people to be healthier as they live longer. The Company’s initial emphasis is on “senolytics”—therapeutics that selectively eliminate senescent cells that accumulate with age. Unity’s first clinical programs are expected to include inflammatory joint diseases (osteoarthritis) and ophthalmology (glaucoma and age related macular degeneration).

Genocea Biosciences

Sofie Biosciences, Inc.

Urban Electric Power, Inc.

Centaur Pharm. / Renovis

Sirtris PharmaceuticalsSirtris Pharmaceuticals is a biopharmaceutical company discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Its drug candidates are designed to mimic the beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins. Sirtris has been acquired by GlaxoSmithKline (NYSE:GSK).

Unity Biotechnology, Inc.

Fziomed Inc.

Sirtris

Sofie Biosciences, Inc.Sofie combines novel tools for PET imaging and radiosynthesis with a full line of imaging and radiochemistry systems and a premier radiopharmacy network and contract manufacturing organization to supply novel agents for diagnosis and therapy.

Alsius Corporation ALSIUS (Latin translation for “Cool”) is the worldwide leader in advanced patient temperature management therapies. Alsius Intravascular Temperature Management™ gives health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. Alsius has been acquired by a wholly-owned subsidiary of ZOLL Medical Corporation (Nasdaq:ZOLL).

Tap to explore our portfolio of companies… some current, and some we have exited.

Agile RF, Inc. Agile RF uses a novel material technology to design and fabricate tunable integrated components that have a wide range of applications in wireless communications. The key feature of Agile’s components and circuits is tunability; making their products much more than simply integrated passive circuits. Agile’s expertise in materials science and RF circuit design has enabled them to exploit the properties of newly developed thin film materials in innovative RF designs. Agile has exclusively licensed certain of its key technologies to TriQuint (Nasdaq:TNQT).

Imaginab, Inc.ImaginAb facilitates the promise of personalized medicine through creation of companion diagnostics for patient stratification and targeted molecular therapy. ImaginAb’s technology enables antibodies to be re-engineered into smaller proteins (fragments) with rapid kinetics suitable for diagnostic imaging, while maintaining target biospecificity. In this way true companion in vivo diagnostics can be developed that enable target expression to be profiled in tissues in a non-invasive, whole-body manner.

Ziopharm Oncology, Inc.ZIOPHARM is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.(Nasdaq:ZIOP)

CalimmuneCalimmune is committed to accelerating the promise of gene therapy to liberate patients from chronic and currently incurable diseases. To achieve this goal, Calimmune has built a suite of technologies to advance the delivery, manufacturing, and overall efficiency of these life-changing medicines. Calimmune’s lead development programs are novel ex vivo gene therapies for HIV and other hematologic diseases. Calimmune has been acquired by CSL Behring (ASX:CSL).

Universal Space NetworkFounded by aerospace pioneer Charles “Pete” Conrad, Jr., Universal Space Network, Inc. (USN) is a leader in space operations for telemetry, tracking and control (TT&C) services. Offering responsive, reliable and cost-effective solutions to the global government and commercial space community, USN provides unparalleled coverage through a seamless network of worldwide satellite tracking and communications assets. USN has been acquired by The Swedish Space Corporation.

Tilford Pinson Exploration, LLC

Explore our portfolio of companies… some current, and some we have exited.

Sterifx, Inc.SteriFx, Inc. is a specialty chemical company producing non-toxic antimicrobial solutions for the food safety, industrial, consumer, healthcare, and military/homeland defense markets. The patented technology is a low pH (<1) aqueous solution that is highly effective in controlling pathogens (viruses, bacteria and fungi) with no toxicity when properly used. The Company’s products have received regulatory approvals from the USDA/FSIS, EPA and FDA for a variety of applications. SteriFx was acquired in a private transaction.

Clean Diesel Technologies / Catalytic Solutions, Inc.

Sterifx, Inc.SteriFx, Inc. is a specialty chemical company producing non-toxic antimicrobial solutions for the food safety, industrial, consumer, healthcare, and military/homeland defense markets. The patented technology is a low pH (<1) aqueous solution that is highly effective in controlling pathogens (viruses, bacteria and fungi) with no toxicity when properly used. The Company’s products have received regulatory approvals from the USDA/FSIS, EPA and FDA for a variety of applications. SteriFx was acquired in a private transaction.

805.684.6515 1270 Coast Village Circle, Suite 100 Santa Barbara, CA 93108 fax: 805.684.6511

SEND

Message

Moon is red or white?

Name

All fields are required.

Please answer this question to help stop spam.

Subject

All fields are required.

Please answer this question to help stop spam.

Moon is red or white?